1. Home
  2. MC vs ARQT Comparison

MC vs ARQT Comparison

Compare MC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$68.02

Market Cap

4.0B

Sector

Finance

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$23.21

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MC
ARQT
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.3B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
MC
ARQT
Price
$68.02
$23.21
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$72.88
$34.00
AVG Volume (30 Days)
1.0M
973.7K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
3.87%
N/A
EPS Growth
N/A
88.79
EPS
0.75
N/A
Revenue
N/A
$376,072,000.00
Revenue This Year
$18.28
$34.85
Revenue Next Year
$17.22
$29.39
P/E Ratio
$89.08
N/A
Revenue Growth
N/A
91.34
52 Week Low
$51.06
$12.42
52 Week High
$78.22
$31.77

Technical Indicators

Market Signals
Indicator
MC
ARQT
Relative Strength Index (RSI) 71.42 45.73
Support Level $60.61 $22.56
Resistance Level $73.46 $23.46
Average True Range (ATR) 2.30 0.89
MACD 0.60 -0.06
Stochastic Oscillator 83.84 25.17

Price Performance

Historical Comparison
MC
ARQT

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: